Individual experimental treatment attempt at Hopp Children’s Cancer Center Heidelberg (KiTZ) and Heidelberg University Hospital (UKHD) using a TC...
Bavarian Nordic A/S announced that the Swiss Agency for Therapeutic Products, Swissmedic, has approved VIMKUNYA® (recombinant, adsorbed) for active i...
Sana and Mayo Clinic to collaborate across multiple areas with goal of accelerating development of and access to potentially curative therapies for patie...
The Elecsys NfL blood test detects neuroaxonal damage associated with neuroinflammation in adults diagnosed with relapsing remitting multiple sclerosis...
OncoC4 Inc., a late clinical stage biopharmaceutical company, announced first participant's dosing following the clearance of the Investigational New Dru...
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, \announced a strategic collaboration with Precision Health Research...
Innovaccer Inc., a leading healthcare AI company, and Infinia Technologies, a next-generation digital transformation company and a subsidiary of Sirius I...
Nxera Pharma Co., Ltd. announces that it has achieved a second development milestone under its multi-target collaboration and license agreement with Eli ...
Strengthens three community health models spanning community‑embedded care, earlier intervention and data‑driven population health Scales program ...
Company expands strategic focus into one of oncology’s most urgent supportive-care challenges Curanex Pharmaceuticals, Inc. (Nasdaq: CURX) (&...
BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dis...
Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with exte...
Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”), a clinical-stage biotechnology company focused on oncology and AI-dr...
Rinzimetostat 400 mg once daily selected as RP3D in combination with darolutamide for Himalayas-1 global Phase 3 registrational trial in post-abiraterone...
© 2026 Biopharma Boardroom. All Rights Reserved.
